SpinePhase 4MgNmNCT06975072
Effect of Magnesium on Neuromonitoring
A Phase 4 study testing Magnesium sulfate administration in people with Spine and Pain, run by University of California, San Francisco at 1 site in United States.
Trial summary
Intraoperative neurophysiologic monitoring (IONM) is commonly used during complex spinal surgery to monitor the integrity of neural structures and improve the perioperative safety profile. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Spine, Pain, Spine Surgery
- What is being tested?
- Magnesium sulfate administration
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2025to 30 Dec 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients (>18 years of age) undergoing open thoracolumbar fusion with planned neuromonitoring
Who cannot join
- Patients with a history of significant cardiac disease (LVEF <35%, 2nd/3rd-degree block without a pacemaker, or significant arrhythmia)
- Patients with kidney disease (GFR <30), or hepatic dysfunction (history of cirrhosis)
- Allergy or sensitivity to magnesium
- Patient with neuromuscular disease such as myasthenia graves
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of California San Francisco Hospital
San Francisco, California, 94143
Hear Cil MD, 415-502-7846, hemra.cil@ucsf.edu
About this study
Official title: Pharmacokinetics and Impact of Magnesium Sulfate on Neuromonitoring in Spinal Surgery
Intraoperative neurophysiologic monitoring (IONM) is commonly used during complex spinal surgery to monitor the integrity of neural structures and improve the perioperative safety profile. Transcranial Motor Evoked Potentials (TcMEPs) monitor the integrity of the motor pathways and are one of the most commonly used monitoring modalities in spinal surgery. Because inhaled anesthetics can negatively affect the ability to monitor TcMEPs, anesthesiologists commonly use a combination of propofol and opioids to maintain the anesthetic state. Additionally, anesthesiologists will frequently administer intravenous infusions of medications that can decrease postoperative pain and opioid use (called opioid-sparing adjuncts) because spinal surgeries result in significant postoperative pain. Despite the increasing use of these agents, there is scant clinical data about how they may affect the integrity of TcMEP monitoring. Magnesium (Mg), a N-methyl-d-aspartate receptors (NMDA) receptor antagonist, is one of the adjuncts with robust data supporting clinical efficacy to decrease pain and opioid use on TcMEPs. Mg has been used clinically for decades. The investigators commonly utilize intravenous magnesium as a component of our spinal anesthesia protocol. However, there is only a single case report that discusses the effects of Mg on TcMEPs. Here the investigators propose a prospective clinical trial to quantitatively assess the effects of various Mg plasma levels on TcMEPs. There is a lack of literature on the pharmacokinetics of magnesium in non-pregnant patients.
Read the detailed description
Spinal surgeries continue to increase in frequency and complexity, with the potential to cause injury to neural structures. Intraoperative neurophysiologic monitoring (IONM) is a crucial tool in spinal surgery, offering real-time detection of adverse changes in the integrity of neural systems governing sensory and motor function. At the same time, the patient is anesthetized, which decreases the risk of permanent and severe neuronal injury. Transcranial Motor Evoked Potentials (TcMEPs), which involve nonspecific stimulation of pyramidal axons in the cerebral motor cortex while monitoring myogenic responses in various muscle groups, are the most common IONM technique during complex spinal surgeries to assess the integrity of motor pathways. Injury to either the cord or nerve roots is detected as a change in the amplitude or latency of the myogenic response, and this test has very high sensitivity and specificity for injury. Many factors, such as hypotension, hypothermia, anemia, and anesthetics, can affect the amplitude/ latency of TcMEPs. Early during the development of this monitoring modality, it was recognized that volatile inhaled anesthetics severely inhibited the ability to elicit reliable TcMEP data. Clinical trials showed that using propofol, an intravenous (iv) general anesthetic, combined with moderate doses of opioids facilitated high-quality IONM while providing appropriate anesthetic conditions for surgery. While the propofol/opioid combination became the "default" anesthetic as the frequency of IONM increased, there was increasing recognition that anesthesiologists could enhance the perioperative recovery profile by adding iv opioid-sparing adjuncts like ketamine, lidocaine, and magnesium (Mg) to the intraoperative regimen. Furthermore, with the development of enhanced recovery after surgery (ERAS) protocols, nearly all spinal surgeries (except for the most minor procedures) now utilize at least one of these adjuncts. However, while these agents are increasingly used for spinal surgeries, there is scant clinical data about how they may affect the integrity of TcMEP monitoring. High-quality IONM monitoring is invaluable for improving the perioperative safety profile of patients undergoing spinal surgery. However, there is a lack of rigorous quantitative data on the effects of anesthetic adjuncts on TcMEPs. Therefore, the investigators seek to establish a robust protocol that can be used quantitively to determine the impact of these agents on TcMEPs. Our overall hypothesis is that anesthetic adjuncts can variably affect TcMEPs. To establish this protocol, the investigators selected Mg to develop and optimize our protocol. Mg, an NMDA receptor antagonist, is commonly used to reduce postoperative pain and opioid use during major spinal surgery; however, to date, there is only a single case report that discusses the effects of Mg on TcMEPs. However, substantial literature shows that Mg can adversely affect neuromuscular physiology, including through decreased release of acetylcholine from presynaptic neurons and by directly suppressing current flux through muscle-based nicotinic acetylcholine receptors. These effects may explain the clinical observation that higher Mg doses can dose-dependently suppress TcMEPs. While there is a similar dearth of information regarding the effect of the other anesthetic adjuncts on TcMEPs, the investigators propose to begin our investigation and protocol optimization with Mg because of its long use in clinical practice, its safety profile, its effectiveness as an opioid-sparing adjunct, the frequency with which it is used in spinal surgery (an estimated frequency of >75% of patients that receive IONM and the dearth of quantitative data on its effects on TcMEPs. The optimized protocol and initial data will support a more extensive future trial to systemically characterize the effects of all the common anesthetic adjuncts on TcMEPs. High-quality data that quantitatively determine the effects of Mg on TcMEPs will allow clinicians to rationally select effective doses that provide analgesia while ensuring high-quality intraoperative monitoring.
Patient Recruitment: The investigators will use the surgical schedule and CaseView to screen for eligible patients. The PI will determine eligibility by a medical record review, performed prior to the patients surgery and attempts at patient contact. Eligibility will be determined according to the criteria listed in the relevant sections. Briefly, eligible patients are adults >18 years of age, presenting for elective spinal fusion procedures. Before the investigators begin recruitment, all surgeons involved with spine surgery will be contacted by email to inform them about the study and to receive approval for their patients to participate. After each patient has provided informed consent, the investigators will contact the surgeons by email to inform them of the patient's participation.
Consent: The investigators will attempt to obtain eConsent from study subjects prior to arrival at the hospital, however, this may not be possible in all situations. Some of our patients may consent to the procedure, but be unable to complete the eConsent process prior to arrival because of a lack of technical capacity. Day of surgery written consent will only be used as a last resort if the investigators are unable to obtain eConsent. The investigators will obtain verbal consent at least 1 day prior to the scheduled procedure for any patient that cannot provide eConsent, and then obtain written hard copy consent on the day of surgery.
Operating Room: All study patients will undergo general anesthesia like non-study patients. The anesthesia time will not be extended for any study-related activities. The investigators will complete study-related activities during the anesthesia and surgery time without interrupting the standard care.
All patients will receive a standardized anesthetic, an intravenous anesthetic consisting of only propofol (60-150 mcg/kg/min) and remifentanil (0.1-0.3mcg/kg/min. Propofol will be titrated to achieve a Patient State Index (PSI) between 25 and 50 as measured using a standard SEDline Brain Function Monitor (Masimo, Inc., Irvine, CA). Anesthesiologists will be asked to avoid electroencephalographic burst suppression by adjusting the dose of propofol since prior studies have shown that burst suppression can interfere with TcMEPs. This is a standard anesthesia care for our patient care protocol and the investigators would like to avoid electroencephalographic burst suppression in patients undergoing general anesthesia. Patient will have the necessary equipment for neuromonitoring placed. These pieces of equipment are placed identically for patients who are or are not in our study, and the investigators will not add any additional monitors. All patients participating in the study will have neuromonitoring as part of their surgery, so this is not an additional study-specific procedure. Baseline motor-evoked potential data will then be collected. This baseline data is also standard practice and not a study-specific procedure. After the baseline data is collected, the investigators will commence with the study protocol. A single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min).
Mg plasma levels: Blood samples will be collected to measure plasma magnesium (Mg) levels at the following time points: 0 min (pre-Mg administration), 1 min, 10 min (end of infusion), 20 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, and 12 hr. The dosing and blood sampling intervals were determined by the reported half-life of Mg and in consultation with our pharmacology consultant. Blood will be sent to the UCSF Clinical laboratory.
Control group: a control cohort from the same spine patient population to provide a robust comparative baseline. This control cohort will be treated under the exact same anesthetic and neuromonitoring protocol as the completed study, except these patients will not receive magnesium. This addition of a control cohort will help distinguish Mg-specific effects on neuromonitoring from underlying surgical or anesthetic responses and enhance the scientific value of our study, thereby generating high-quality preliminary data.
- Conditions
- Spine, Pain, Spine Surgery, Spine Surgery With Neuromonitoring, Spine Surgery With Motor Evoked Potential Monitoring, Spine Fusion
- Being tested
- Magnesium sulfate administration
- Keywords
- spine, spine surgery, spine fusion, magnesium, neuromonitoring, motor evoked potential monitoring
- Medical subject headings
- Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnesium sulfate administrationDrug
A single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min). Control group will not have any Mg administration
| Study group | Role | What they receive |
|---|---|---|
| Magnesium Arm | Experimental | A single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min). Receives: Drug: Magnesium sulfate administration |
| Control group | No intervention | Control group will have the same anesthesia protocol without Mg administration |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum Magnesium level
Serum magnesium level will be measured by UCSF Lab.
Measured: Through study completion, an average of 1 year
Magnesium- Pharmakokinetics Clearance (CL)
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the Pharmakokinetics clearance (CL) data with the levels.
Measured: Through study completion, an average of 1 year
Magnesium- Pharmacokinetics central volume of distribution (Vc)
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the Pharmacokinetics Central volume of distribution (Vc) data with the levels.
Measured: Through study completion, an average of 1 year
Magnesium- Pharmakokinetics (PK) intercompartmental clearance (Q)
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the PK intercompartmental clearance (Q) data with the levels.
Measured: Through study completion, an average of 1 year
Magnesium- Pharmakokinetics peripheral volume of distribution (Vp)
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the PK peripheral volume of distribution (Vp) data with the levels.
Measured: Through study completion, an average of 1 year
Secondary outcomes (3)
Neuromonitoring data-Stimulation voltage
The investigators will change in stimulation voltage in different time points using the students t-test
Measured: Through study completion, an average of 1 year
Neuromonitoring data- motor-evoked potential (MEP) amplitude
The investigators will compare motor-evoked potential (MEP) amplitude responses at different time points using the students t-test.
Measured: Through study completion, an average of 1 year
Neuromonitoring data- Motor Evoked Potential (MEP) Latency
The investigators will compare the change in MEP latency using the students t-test
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2025
- Study start1 Jul 2025
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (10)Papers the sponsor has linked to this study.
- Other trials for SpineStudies of the same condition, open and under way.
- More trials run by University of California, San FranciscoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hemra Cil, MD, Principal investigator, University of California, San Francisco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06975072
- Sponsor's protocol ID
- 25-43430
- Acronym
- MgNm
- Status last verified
- Aug 2026
- First submitted
- 31 Mar 2025
- Last updated
- 21 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Blacker SN, Vincent A, Burbridge M, Bustillo M, Hazard SW, Heller BJ, Nadler JW, Sullo E, Lele AV; Society for Neuroscience in Anesthesiology and Critical Care. Perioperative Care of Patients Undergoing Major Complex Spinal Instrumentation Surgery: Clinical Practice Guidelines From the Society for Neuroscience in Anesthesiology and Critical Care. J Neurosurg Anesthesiol. 2022 Jul 1;34(3):257-276. doi: 10.1097/ANA.0000000000000799. Epub 2021 Sep 6.
PubMed 34483301Johnson T, Kale EB, Husain AM. Magnesium Sulfate-Induced Motor Evoked Potential Changes. Neurodiagn J. 2018;58(2):83-90. doi: 10.1080/21646821.2018.1469336.
PubMed 29923809Wang H, Liang QS, Cheng LR, Li XH, Fu W, Dai WT, Li ST. Magnesium sulfate enhances non-depolarizing muscle relaxant vecuronium action at adult muscle-type nicotinic acetylcholine receptor in vitro. Acta Pharmacol Sin. 2011 Dec;32(12):1454-9. doi: 10.1038/aps.2011.117. Epub 2011 Oct 10.
PubMed 21986576Yue L, Lin ZM, Mu GZ, Sun HL. Impact of intraoperative intravenous magnesium on spine surgery: A systematic review and meta-analysis of randomized controlled trials. EClinicalMedicine. 2022 Jan 5;43:101246. doi: 10.1016/j.eclinm.2021.101246. eCollection 2022 Jan.
PubMed 35028543Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005 Apr 1;95(7):915-8. doi: 10.1016/j.amjcard.2004.11.055.
PubMed 15781034Furutani K, Deguchi H, Matsuhashi M, Mitsuma Y, Kamiya Y, Baba H. A Bolus Dose of Ketamine Reduces the Amplitude of the Transcranial Electrical Motor-evoked Potential: A Randomized, Double-blinded, Placebo-controlled Study. J Neurosurg Anesthesiol. 2021 Jul 1;33(3):230-238. doi: 10.1097/ANA.0000000000000653.
PubMed 31633576Tramer MR, Schneider J, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology. 1996 Feb;84(2):340-7. doi: 10.1097/00000542-199602000-00011.
PubMed 8602664Herdmann J, Deletis V, Edmonds HL Jr, Morota N. Spinal cord and nerve root monitoring in spine surgery and related procedures. Spine (Phila Pa 1976). 1996 Apr 1;21(7):879-85. doi: 10.1097/00007632-199604010-00023.
PubMed 8779023Sloan TB, Heyer EJ. Anesthesia for intraoperative neurophysiologic monitoring of the spinal cord. J Clin Neurophysiol. 2002 Oct;19(5):430-43. doi: 10.1097/00004691-200210000-00006.
PubMed 12477988Macdonald DB, Skinner S, Shils J, Yingling C; American Society of Neurophysiological Monitoring. Intraoperative motor evoked potential monitoring - a position statement by the American Society of Neurophysiological Monitoring. Clin Neurophysiol. 2013 Dec;124(12):2291-316. doi: 10.1016/j.clinph.2013.07.025. Epub 2013 Sep 18.
PubMed 24055297
Study at a glance
From the registry record, last updated by the sponsor on 21 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pharmacokinetics and Impact of Magnesium Sulfate on Neuromonitoring in Spinal Surgery
- ClinicalTrials.gov ID
- NCT06975072
- Acronym / sponsor ID
- MgNm / 25-43430
- Conditions
- Spine, Pain, Spine Surgery, Spine Surgery With Neuromonitoring, Spine Surgery With Motor Evoked Potential Monitoring, Spine Fusion
- Keywords
- spine, spine surgery, spine fusion, magnesium, neuromonitoring, motor evoked potential monitoring
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University of California, San FranciscoUniversity, hospital or other
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 16 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intraoperative neurophysiologic monitoring (IONM) is commonly used during complex spinal surgery to monitor the integrity of neural structures and improve the perioperative safety profile. Transcranial Motor Evoked Potentials (TcMEPs) monitor the integrity of the motor pathways and are one of the most commonly used monitoring modalities in spinal surgery. Because inhaled anesthetics can negatively affect the ability to monitor TcMEPs, anesthesiologists commonly use a combination of propofol and opioids to maintain the anesthetic state. Additionally, anesthesiologists will frequently administer intravenous infusions of medications that can decrease postoperative pain and opioid use (called opioid-sparing adjuncts) because spinal surgeries result in significant postoperative pain. Despite the increasing use of these agents, there is scant clinical data about how they may affect the integrity of TcMEP monitoring. Magnesium (Mg), a N-methyl-d-aspartate receptors (NMDA) receptor antagonist, is one of the adjuncts with robust data supporting clinical efficacy to decrease pain and opioid use on TcMEPs. Mg has been used clinically for decades. The investigators commonly utilize intravenous magnesium as a component of our spinal anesthesia protocol. However, there is only a single case report that discusses the effects of Mg on TcMEPs. Here the investigators propose a prospective clinical trial to quantitatively assess the effects of various Mg plasma levels on TcMEPs. There is a lack of literature on the pharmacokinetics of magnesium in non-pregnant patients.
Detailed description
Spinal surgeries continue to increase in frequency and complexity, with the potential to cause injury to neural structures. Intraoperative neurophysiologic monitoring (IONM) is a crucial tool in spinal surgery, offering real-time detection of adverse changes in the integrity of neural systems governing sensory and motor function. At the same time, the patient is anesthetized, which decreases the risk of permanent and severe neuronal injury. Transcranial Motor Evoked Potentials (TcMEPs), which involve nonspecific stimulation of pyramidal axons in the cerebral motor cortex while monitoring myogenic responses in various muscle groups, are the most common IONM technique during complex spinal surgeries to assess the integrity of motor pathways. Injury to either the cord or nerve roots is detected as a change in the amplitude or latency of the myogenic response, and this test has very high sensitivity and specificity for injury. Many factors, such as hypotension, hypothermia, anemia, and anesthetics, can affect the amplitude/ latency of TcMEPs. Early during the development of this monitoring modality, it was recognized that volatile inhaled anesthetics severely inhibited the ability to elicit reliable TcMEP data. Clinical trials showed that using propofol, an intravenous (iv) general anesthetic, combined with moderate doses of opioids facilitated high-quality IONM while providing appropriate anesthetic conditions for surgery. While the propofol/opioid combination became the "default" anesthetic as the frequency of IONM increased, there was increasing recognition that anesthesiologists could enhance the perioperative recovery profile by adding iv opioid-sparing adjuncts like ketamine, lidocaine, and magnesium (Mg) to the intraoperative regimen. Furthermore, with the development of enhanced recovery after surgery (ERAS) protocols, nearly all spinal surgeries (except for the most minor procedures) now utilize at least one of these adjuncts. However, while these agents are increasingly used for spinal surgeries, there is scant clinical data about how they may affect the integrity of TcMEP monitoring. High-quality IONM monitoring is invaluable for improving the perioperative safety profile of patients undergoing spinal surgery. However, there is a lack of rigorous quantitative data on the effects of anesthetic adjuncts on TcMEPs. Therefore, the investigators seek to establish a robust protocol that can be used quantitively to determine the impact of these agents on TcMEPs. Our overall hypothesis is that anesthetic adjuncts can variably affect TcMEPs. To establish this protocol, the investigators selected Mg to develop and optimize our protocol. Mg, an NMDA receptor antagonist, is commonly used to reduce postoperative pain and opioid use during major spinal surgery; however, to date, there is only a single case report that discusses the effects of Mg on TcMEPs. However, substantial literature shows that Mg can adversely affect neuromuscular physiology, including through decreased release of acetylcholine from presynaptic neurons and by directly suppressing current flux through muscle-based nicotinic acetylcholine receptors. These effects may explain the clinical observation that higher Mg doses can dose-dependently suppress TcMEPs. While there is a similar dearth of information regarding the effect of the other anesthetic adjuncts on TcMEPs, the investigators propose to begin our investigation and protocol optimization with Mg because of its long use in clinical practice, its safety profile, its effectiveness as an opioid-sparing adjunct, the frequency with which it is used in spinal surgery (an estimated frequency of >75% of patients that receive IONM and the dearth of quantitative data on its effects on TcMEPs. The optimized protocol and initial data will support a more extensive future trial to systemically characterize the effects of all the common anesthetic adjuncts on TcMEPs. High-quality data that quantitatively determine the effects of Mg on TcMEPs will allow clinicians to rationally select effective doses that provide analgesia while ensuring high-quality intraoperative monitoring.
Patient Recruitment: The investigators will use the surgical schedule and CaseView to screen for eligible patients. The PI will determine eligibility by a medical record review, performed prior to the patients surgery and attempts at patient contact. Eligibility will be determined according to the criteria listed in the relevant sections. Briefly, eligible patients are adults >18 years of age, presenting for elective spinal fusion procedures. Before the investigators begin recruitment, all surgeons involved with spine surgery will be contacted by email to inform them about the study and to receive approval for their patients to participate. After each patient has provided informed consent, the investigators will contact the surgeons by email to inform them of the patient's participation.
Consent: The investigators will attempt to obtain eConsent from study subjects prior to arrival at the hospital, however, this may not be possible in all situations. Some of our patients may consent to the procedure, but be unable to complete the eConsent process prior to arrival because of a lack of technical capacity. Day of surgery written consent will only be used as a last resort if the investigators are unable to obtain eConsent. The investigators will obtain verbal consent at least 1 day prior to the scheduled procedure for any patient that cannot provide eConsent, and then obtain written hard copy consent on the day of surgery.
Operating Room: All study patients will undergo general anesthesia like non-study patients. The anesthesia time will not be extended for any study-related activities. The investigators will complete study-related activities during the anesthesia and surgery time without interrupting the standard care.
All patients will receive a standardized anesthetic, an intravenous anesthetic consisting of only propofol (60-150 mcg/kg/min) and remifentanil (0.1-0.3mcg/kg/min. Propofol will be titrated to achieve a Patient State Index (PSI) between 25 and 50 as measured using a standard SEDline Brain Function Monitor (Masimo, Inc., Irvine, CA). Anesthesiologists will be asked to avoid electroencephalographic burst suppression by adjusting the dose of propofol since prior studies have shown that burst suppression can interfere with TcMEPs. This is a standard anesthesia care for our patient care protocol and the investigators would like to avoid electroencephalographic burst suppression in patients undergoing general anesthesia. Patient will have the necessary equipment for neuromonitoring placed. These pieces of equipment are placed identically for patients who are or are not in our study, and the investigators will not add any additional monitors. All patients participating in the study will have neuromonitoring as part of their surgery, so this is not an additional study-specific procedure. Baseline motor-evoked potential data will then be collected. This baseline data is also standard practice and not a study-specific procedure. After the baseline data is collected, the investigators will commence with the study protocol. A single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min).
Mg plasma levels: Blood samples will be collected to measure plasma magnesium (Mg) levels at the following time points: 0 min (pre-Mg administration), 1 min, 10 min (end of infusion), 20 min, 30 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, and 12 hr. The dosing and blood sampling intervals were determined by the reported half-life of Mg and in consultation with our pharmacology consultant. Blood will be sent to the UCSF Clinical laboratory.
Control group: a control cohort from the same spine patient population to provide a robust comparative baseline. This control cohort will be treated under the exact same anesthetic and neuromonitoring protocol as the completed study, except these patients will not receive magnesium. This addition of a control cohort will help distinguish Mg-specific effects on neuromonitoring from underlying surgical or anesthetic responses and enhance the scientific value of our study, thereby generating high-quality preliminary data.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Magnesium Arm | Experimental | Drug: Magnesium sulfate administrationA single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min). |
| Control group | No intervention | –Control group will have the same anesthesia protocol without Mg administration |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Adult patients (>18 years of age) undergoing open thoracolumbar fusion with planned neuromonitoring
Key exclusion criteria (4 listed)
- Patients with a history of significant cardiac disease (LVEF <35%, 2nd/3rd-degree block without a pacemaker, or significant arrhythmia)
- Patients with kidney disease (GFR <30), or hepatic dysfunction (history of cirrhosis)
- Allergy or sensitivity to magnesium
- Patient with neuromuscular disease such as myasthenia graves
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnesium sulfate administrationA single intravenous bolus of Mg of 30mg/kg (based on ideal body weight) will be administered over a period of 10 minutes (min). Control group will not have any Mg administration | Drug | Magnesium Arm |
Primary outcome
Serum Magnesium level
Time frame: Through study completion, an average of 1 year
Serum magnesium level will be measured by UCSF Lab.
Magnesium- Pharmakokinetics Clearance (CL)
Time frame: Through study completion, an average of 1 year
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the Pharmakokinetics clearance (CL) data with the levels.
Magnesium- Pharmacokinetics central volume of distribution (Vc)
Time frame: Through study completion, an average of 1 year
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the Pharmacokinetics Central volume of distribution (Vc) data with the levels.
Magnesium- Pharmakokinetics (PK) intercompartmental clearance (Q)
Time frame: Through study completion, an average of 1 year
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the PK intercompartmental clearance (Q) data with the levels.
Magnesium- Pharmakokinetics peripheral volume of distribution (Vp)
Time frame: Through study completion, an average of 1 year
Serum magnesium level will be measured by UCSF Lab. Then the investigators will run the PK peripheral volume of distribution (Vp) data with the levels.
3 secondary outcomes
Neuromonitoring data-Stimulation voltage
Time frame: Through study completion, an average of 1 year
Neuromonitoring data- motor-evoked potential (MEP) amplitude
Time frame: Through study completion, an average of 1 year
Neuromonitoring data- Motor Evoked Potential (MEP) Latency
Time frame: Through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Aug 2026.
- Background: PubMed 34483301Blacker SN, Vincent A, Burbridge M, Bustillo M, Hazard SW, Heller BJ, Nadler JW, Sullo E, Lele AV; Society for Neuroscience in Anesthesiology and Critical Care. Perioperative Care of Patients Undergoing Major Complex Spinal Instrumentation Surgery: Clinical Practice Guidelines From the Society for Neuroscience in Anesthesiology and Critical Care. J Neurosurg Anesthesiol. 2022 Jul 1;34(3):257-276. doi: 10.1097/ANA.0000000000000799. Epub 2021 Sep 6.
- Background: PubMed 29923809Johnson T, Kale EB, Husain AM. Magnesium Sulfate-Induced Motor Evoked Potential Changes. Neurodiagn J. 2018;58(2):83-90. doi: 10.1080/21646821.2018.1469336.
- Background: PubMed 21986576Wang H, Liang QS, Cheng LR, Li XH, Fu W, Dai WT, Li ST. Magnesium sulfate enhances non-depolarizing muscle relaxant vecuronium action at adult muscle-type nicotinic acetylcholine receptor in vitro. Acta Pharmacol Sin. 2011 Dec;32(12):1454-9. doi: 10.1038/aps.2011.117. Epub 2011 Oct 10.
- Background: PubMed 35028543Yue L, Lin ZM, Mu GZ, Sun HL. Impact of intraoperative intravenous magnesium on spine surgery: A systematic review and meta-analysis of randomized controlled trials. EClinicalMedicine. 2022 Jan 5;43:101246. doi: 10.1016/j.eclinm.2021.101246. eCollection 2022 Jan.
- Background: PubMed 15781034Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005 Apr 1;95(7):915-8. doi: 10.1016/j.amjcard.2004.11.055.
- Background: PubMed 31633576Furutani K, Deguchi H, Matsuhashi M, Mitsuma Y, Kamiya Y, Baba H. A Bolus Dose of Ketamine Reduces the Amplitude of the Transcranial Electrical Motor-evoked Potential: A Randomized, Double-blinded, Placebo-controlled Study. J Neurosurg Anesthesiol. 2021 Jul 1;33(3):230-238. doi: 10.1097/ANA.0000000000000653.
- Background: PubMed 8602664Tramer MR, Schneider J, Marti RA, Rifat K. Role of magnesium sulfate in postoperative analgesia. Anesthesiology. 1996 Feb;84(2):340-7. doi: 10.1097/00000542-199602000-00011.
- Background: PubMed 8779023Herdmann J, Deletis V, Edmonds HL Jr, Morota N. Spinal cord and nerve root monitoring in spine surgery and related procedures. Spine (Phila Pa 1976). 1996 Apr 1;21(7):879-85. doi: 10.1097/00007632-199604010-00023.
- Background: PubMed 12477988Sloan TB, Heyer EJ. Anesthesia for intraoperative neurophysiologic monitoring of the spinal cord. J Clin Neurophysiol. 2002 Oct;19(5):430-43. doi: 10.1097/00004691-200210000-00006.
- Background: PubMed 24055297Macdonald DB, Skinner S, Shils J, Yingling C; American Society of Neurophysiological Monitoring. Intraoperative motor evoked potential monitoring - a position statement by the American Society of Neurophysiological Monitoring. Clin Neurophysiol. 2013 Dec;124(12):2291-316. doi: 10.1016/j.clinph.2013.07.025. Epub 2013 Sep 18.
- Individual participant dataSharing planned: Yes
Related trials for Spine
Active, not recruiting
High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull
Chordoma of Spine, Chordoma of Sacrum
Not yet recruiting
Kore Fiber PLF Study
Degenerative Lumbar Spine Diseases, Lumbar Degenerative Disc Disease
Recruiting
Evaluation of the Statistical Validity of Cervical Spine Measurements-Including Range of Motion, Strength, and Functional Test Results-for Return to Sport in Patients Who Have Undergone Surgery for Cervical Stenosis and/or Herniation.
Cervical Stenosis, Cervical Spine
Recruiting
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
Degenerative Disc Disease, Spine Fusion
Enrolling by invitationObservational study
INDUCE: A Prospective 2-Year Spine Registry
Subjects Treated With NMP as Part of Their Spine Surgery, Degenerative Disc Disease (DDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Hemra Cil, MD principal investigator
University of California, San Francisco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Magnesium sulfate administration in people with Spine and Pain, run by University of California, San Francisco at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hemra Cil, MD (415-502-7846, hemra.cil@ucsf.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum Magnesium level (time frame: Through study completion, an average of 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06975072, which also lists 10 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Aug 2026; AzTrials last refreshed its copy on 26 Oct 2026.